Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Capital Expenditures (2018 - 2025)

Autolus Therapeutics (AUTL) has disclosed Capital Expenditures for 5 consecutive years, with -$14.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Capital Expenditures fell 1028.91% year-over-year to -$14.1 million, compared with a TTM value of $351000.0 through Sep 2025, down 91.96%, and an annual FY2024 reading of $1.8 million, down 83.68% over the prior year.
  • Capital Expenditures was -$14.1 million for Q3 2025 at Autolus Therapeutics, down from $7.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $8.2 million in Q1 2025 and bottomed at -$14.1 million in Q3 2025.
  • Average Capital Expenditures over 4 years is $573500.0, with a median of $1.2 million recorded in 2023.
  • Peak annual rise in Capital Expenditures hit 1446.53% in 2025, while the deepest fall reached 1028.91% in 2025.
  • Year by year, Capital Expenditures stood at -$7.3 million in 2022, then surged by 120.11% to $1.5 million in 2023, then crashed by 174.2% to -$1.1 million in 2024, then tumbled by 1184.03% to -$14.1 million in 2025.
  • Business Quant data shows Capital Expenditures for AUTL at -$14.1 million in Q3 2025, $7.3 million in Q2 2025, and $8.2 million in Q1 2025.